Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Bayer ( (DE:BAYN) ).
Bayer Aktiengesellschaft has announced the upcoming disclosure of its financial reports, including the year report for 2025 and the half-year report for 2026. These reports, set to be published in February and August 2026, respectively, will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders and market perception.
The most recent analyst rating on (DE:BAYN) stock is a Hold with a EUR30.00 price target. To see the full list of analyst forecasts on Bayer stock, see the DE:BAYN Stock Forecast page.
More about Bayer
Bayer Aktiengesellschaft is a global enterprise with core competencies in the life science fields of health care and agriculture. The company is known for its pharmaceutical products, consumer health products, and crop science solutions, focusing on innovation and sustainability to enhance human and plant health.
YTD Price Performance: 47.78%
Average Trading Volume: 2,179,531
Technical Sentiment Signal: Hold
Current Market Cap: €27.91B
Find detailed analytics on BAYN stock on TipRanks’ Stock Analysis page.